May 23, 2025
Source: drugdu
75
520, as the Internet Valentine's Day, is deeply loved by couples. It has now become a popular day for pharmaceutical companies to officially announce cooperation.
Today, a blockbuster news swept the entire pharmaceutical industry: Pfizer invested a huge amount of US$6.05 billion to introduce 3SBio's PD-1/VEGF bispecific antibody SSGJ-707, marking another significant new milestone in China's innovative drug overseas expansion - becoming the domestic license deal project with the highest down payment to date.
However, amid this wave of attention, there is another innovative drug overseas collaboration that cannot be ignored today. That is the major collaboration between Jingyin Pharmaceutical and CRISPR Therapeutics. The two parties will work together to promote the development of innovative siRNA therapies, and the amount of this collaboration is as high as US$895 million (approximately RMB 6.5 billion).
6.5 billion yuan cooperation
On May 20, Jingyin Pharmaceutical announced a strategic partnership with CRISPR Therapeutics, focusing on jointly advancing the development and commercialization of siRNA therapies. There are profound background and reasons behind this.
Jingyin Pharmaceutical has been deeply engaged in the siRNA field for a long time and has a core technology platform for the research and development of small nucleic acid drugs with independent intellectual property rights, covering multiple key links such as targeted delivery systems, chemical modification technology and double-stranded siRNA design. Taking chemical modification technology as an example, it can significantly prolong the stability and half-life of siRNA, thereby ensuring the long-term effect of the drug in the body, which is undoubtedly an important "weapon" for it to stand out from the competition.
As a leader in the field of gene therapy, CRISPR Therapeutics has strong R&D capabilities and rich technical experience. The powerful combination of the two parties aims to organically integrate CRISPR Therapeutics' R&D capabilities with Jingyin Pharmaceutical's siRNA technology platform to bring new hope to patients with thrombosis and thromboembolic diseases.
According to the cooperation agreement signed by both parties, the core project of the cooperation is the next-generation long-acting Factor XI (FXI) targeted small interfering RNA (siRNA) therapy SRSD107, which is mainly used to treat thrombosis and thromboembolic diseases. The development of this drug stems from the key role of the FXI target in pathological thrombosis, and its effect on normal hemostasis is relatively small. The data from preclinical trials are exciting. After a single subcutaneous injection of SRSD107, the concentration of FXI in peripheral blood can be reduced by nearly 100%, and this effect can last for up to half a year, and no obvious bleeding risk is observed. This makes SRSD107 a potential first-in-class and best-in-class new generation of safer anticoagulant drugs.
In terms of the commercial terms of the collaboration, Jingyin Pharmaceutical will receive $95 million in cash and cash equivalents from CRISPR Therapeutics as a down payment, and will be eligible to receive more than $800 million in advance payments and milestone payments. The two parties will jointly develop SRSD107 in accordance with a 50-50 cost and profit sharing mechanism. In addition, in terms of market division of labor, CRISPR will be responsible for the commercialization of SRSD107 in the United States, while Jingyin Pharmaceutical will focus on the Greater China market and is committed to the promotion and sales of the drug in this region.
This cooperation is undoubtedly a major development opportunity for Jingyin Pharmaceutical. On the one hand, the generous financial support provides a solid material guarantee for the research and development of its siRNA therapy, allowing it to devote more attention to the development of innovative drugs; on the other hand, cooperation with an internationally renowned research and development institution such as CRISPR Therapeutics will help enhance Jingyin Pharmaceutical's research and development strength and market competitiveness in the field of siRNA therapy, further enrich and improve its product pipeline, and inject strong impetus into the company's long-term development.
For CRISPR Therapeutics, the cooperation with Jingyin Pharmaceutical can effectively expand its product pipeline layout in the field of cardiovascular diseases. With the help of Jingyin Pharmaceutical's advanced technology in the field of siRNA, CRISPR Therapeutics can further enrich its own treatment technology platform, thereby enhancing its comprehensive competitiveness in the pharmaceutical market.
It is worth mentioning that this is also a landmark event in the field of siRNA therapy, fully demonstrating the industry's high recognition of the huge potential of siRNA technology in the treatment of cardiovascular diseases.
A new path
From cardiovascular disease to cancer patients, the shadow of thromboembolism is everywhere. Thromboembolic diseases are quietly becoming a hidden "killer" of global health.
Data shows that the global anticoagulant market size will reach US$17.8 billion in 2023, and the entire anti-thrombotic drug market will be even larger, with revenue of US$52.4 billion in 2024. It is expected to jump to US$96.42 billion in 2032, with a compound annual growth rate of 7.92% between 2025 and 2032.
However, the limitations of traditional anticoagulation therapy have gradually been exposed. The risk of bleeding caused by excessive anticoagulation is like a sword of Damocles, hanging over the minds of doctors and patients. In the pursuit of a balance between efficacy and safety, siRNA therapy is like a ray of light that penetrates the fog and opens up a new path for thrombosis treatment.
The emergence of siRNA therapy is a perfect interpretation of precision medicine. It precisely targets coagulation factor XI (FXI), blocking the "source" of pathological thrombosis while cleverly avoiding interference with normal hemostasis. Compared with traditional coagulation factor Xa inhibitors, this precision attack has an obvious advantage, just like accurately cutting off a key clue in the intricate coagulation network without touching other important links.
Its long-term effect is a highlight. The preclinical and clinical trial data are amazing. A single subcutaneous injection of SRSD107 can reduce the peripheral blood FXI concentration to almost zero, and this effect can last for half a year. For patients, this not only reduces the pain and inconvenience of frequent dosing, but also improves treatment compliance, making regular treatment no longer a difficult task. In terms of safety, SRSD107 also delivered a brilliant answer. In early trials, it showed good tolerability and did not increase the risk of bleeding.
The potential indications of siRNA therapy are even more impressive. From the cardiovascular risks of patients with atrial fibrillation to the recurrence risks of patients with venous thromboembolism; from the thrombotic complications of tumor patients to the coagulation problems of hemodialysis patients; from the perioperative bleeding risks of patients undergoing orthopedic surgery to the coagulation abnormalities of patients with end-stage renal disease, siRNA therapy has shown a wide range of application prospects and is expected to become a boon for patients with various thrombosis-related diseases.
A new star in innovative nucleic acid therapy
Why did Jingyin Pharmaceutical reach this cooperation? This is related to its deep cultivation of innovative nucleic acid therapy.
Jingyin Pharmaceutical was established in 2021 and is committed to improving human health through innovative nucleic acid therapies. As an emerging biotechnology company, it has shown great potential in the field of cardiovascular and metabolic diseases.
Some of Jingyin Pharmaceutical's pipeline products under development Image source: Yaozhi Data
In the early days, Jingyin Pharmaceutical focused on the treatment of cardiovascular diseases, and SRSD107 injection came into being. As a small interfering RNA (siRNA) therapy targeting coagulation factor XI (FXI), SRSD107 submitted an application for the first human trial (FIH) in Australia in November 2023. Just a few months later, in March 2024, it obtained clinical trial approval from China's CDE. In July of the same year, SRSD107 was the first to complete the Phase I clinical trial in New Zealand, enrolling all subjects and administering the drug, once again verifying its safety and tolerability in populations of different races. In March 2025, Jingyin Pharmaceutical turned its attention to the European market and submitted an application for a Phase II clinical trial to the European Medicines Agency.
The data showed that after a single subcutaneous injection of SRSD107, the peripheral blood FXI concentration was almost completely knocked down, and this effect could last for up to half a year, and no adverse reactions such as bleeding were observed. This groundbreaking research result not only demonstrates the powerful anticoagulant effect of SRSD107, but also highlights its significant advantages in safety.
While the development of SRSD107 is progressing steadily, Jingyin Pharmaceutical has not stopped there and has started the development of SRSD101 injection, a siRNA drug for the treatment of dyslipidemia. In 2024, SRSD101 completed Phase I clinical trials in New Zealand.
SRSD101 effectively reduces LDL-C levels by precisely targeting the PCSK9 gene, and is expected to provide ASCVD patients with a better and more efficient lipid-lowering treatment plan. The development of this innovative therapy not only enriches Jingyin Pharmaceutical's product matrix, but also further consolidates its leading position in the field of cardiovascular disease treatment.
In April 2025, Jingyin Pharmaceutical once again made a breakthrough in the field of new drug research and development. The clinical trial application for SRSD216 injection was approved by the US FDA, and then the first subject was dosed in the Phase I clinical trial in China on April 8.
From SRSD107 to SRSD101, and then to SRSD216, Jingyin Pharmaceutical's pipeline of drugs under development covers multiple cardiovascular metabolic disease treatment areas such as thromboembolic diseases and dyslipidemia, all of which have demonstrated strong innovation and clinical value, and have the potential to be the first or best in their class. They are expected to stand out in future market competition and reshape the treatment landscape of cardiovascular diseases.
https://news.yaozh.com/archive/45490.html
By editoryour submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.